CERT

Analyst Note: CERT (Certara, Inc.)

Date: 2026-06-13 Current Price: $5.54

1. Structural Readiness

• State: Avoid.
• Conservative Entry: Not yet defined (awaiting breakout confirmation).
• Aggressive/Pre-Breakout Entry: Not actionable on setup alone; price is holding above the structural support level but has not triggered the breakout signal.
• Breakout Level: Not yet fired.
• Current Price: $5.54.
• Extension: Not applicable (price has not extended from a breakout).
• ATR Context: Current ATR is 6.8% (Very High). This indicates elevated volatility, which increases the risk of whipsaws during the formation phase.

2. Thesis Layer

• Thesis Classification: Tactical / Setup-Led.
• Secular Exposure: No named secular thesis is active for this specific setup at this date.
• Judgment Framework: The investment case must be judged strictly on the quality of the technical setup (which is currently forming, not confirmed) and the underlying business fundamentals. There is no macro or secular tailwind explicitly named in the current setup parameters to override the technical "Avoid" status.

3. Business Overview

Certara, Inc. operates as a global leader in biosimulation science, technology, and consulting services, specializing in Model-Informed Drug Development (MIDD). The company serves the biopharmaceutical and biotech industries, helping to accelerate the delivery of new medicines.

• Business Model: The company generates revenue through a mix of software licensing and professional services (consulting, regulatory writing, and data services).
• Key Metrics & Evidence (as of May 2026):
• Revenue Guidance: Management expects 2026 full-year revenue to be between $395 million and $405 million, including $18 million from a divested business. Excluding the divested business, full-year growth is expected to be 0% to 4%.
• Software Growth: Software bookings (Trailing 12-month) were $192.3 million, up 8% year-on-year. Software revenue for the quarter ended March 31, 2026, increased 7% to $49.7 million.
• Retention: Net Retention Rates were 106.1% (Q1 2026) compared to 102.4% in the prior period, indicating strong expansion within the existing customer base.
• Recent M&A: On May 8, 2026, the company completed the sale of its global medical writing and regulatory services business to Veristat, LLC for $85.0 million in cash plus $15.0 million in escrow. This divestiture is factored into the current revenue guidance.
• Market Position: Certara states that customers leveraging its solutions have received 90% or more of all new FDA drug approvals since 2014. The software is licensed by over 160,000 users and used by 20 global regulatory agencies, including the FDA.
• Product Innovation: In 2025, the company introduced 103 new software applications and upgrades, including AI-driven modules like Phoenix Cloud's AI PK reports.

4. Archetype and Conviction

• Archetype: Deep Value Recovery.
• Fit Analysis: The "Deep Value Recovery" archetype fits the current price action ($5.54) relative to the company's established market position and the recent divestiture of a non-core business. The company is pivoting toward a higher-margin, scalable software model (evidenced by the 8% growth in software bookings and 106% net retention) while shedding lower-margin services.
• Valuation Context: The financial spine indicates a forward consensus EPS of $0.38 for FY1 and $0.41 for FY2. At a price of $5.54, the stock trades at approximately 14.5x forward FY1 EPS.
• Conviction Stack:
• Thesis Strength: Low (Tactical only; no named macro thesis).
• Evidence Quality: High. The evidence base is robust, with clear guidance, specific booking numbers, and confirmed divestiture details from May 2026.
• Structural Quality: Moderate. The setup is "Forming," meaning the structure is present but unconfirmed. The "Very High" ATR (6.8%) suggests significant noise and risk during the formation phase.
• Setup Readiness: Low. The breakout has not fired. The "Avoid" state is appropriate until the price confirms a move above the resistance level with volume.
• Rerating Potential: Moderate. The shift toward software and AI integration (MIDD) offers a path to multiple expansion, but the current 0-4% revenue growth guidance limits immediate upside momentum.

5. Invalidations, Strengths, and Gaps

• Gaps in Evidence:
• Breakout Level: The specific price target for the breakout is not defined.
• Margin Data: While software growth is highlighted, specific operating margin figures for the post-divestiture business are not explicitly detailed in the provided evidence, though implied by the shift in strategy.

PRIVATE ANALYST CALL

Judgment: Hold Confidence: medium Key evidence: 1) Software bookings grew 8% YoY to $192.3M with 106.1% net retention; 2) Divestiture of medical writing business completed for $85M cash + $15M escrow; 3) Revenue guidance of $395M-$405M implies 0-4% growth, limiting immediate upside; 4) Technical setup is "Forming" with "Very High" ATR (6.8%), indicating elevated volatility without confirmed breakout. Sizing hint: Position size should be minimal or zero until the breakout fires; current volatility suggests a small speculative allocation only if the trader is comfortable with the "Forming" state risk. Expected horizon: 3 to 6 months for the technical setup to resolve (breakout or invalidation).